Bulk Pharmaceutical API Sources for BENDEKA

Bulk Pharmaceutical API Sources for BENDEKA

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		77082
MolPort		MolPort-006-823-040
AAA Chemistry		AR-1G0244
ABI Chem		AC1L2SBO

BENDEKA Bulk API Sourcing Analysis

Last updated: February 19, 2026

This report identifies key bulk active pharmaceutical ingredient (API) suppliers for Bendamustine Hydrochloride, the API in Bendeka. The analysis focuses on manufacturers with established Good Manufacturing Practice (GMP) certifications, significant production capacity, and a history of regulatory compliance. Understanding the current API supply landscape is critical for ensuring consistent product availability, managing manufacturing costs, and mitigating supply chain risks for Bendeka.

Who are the primary bulk API manufacturers for Bendamustine Hydrochloride?

Key manufacturers of bulk Bendamustine Hydrochloride API are located in China and India, countries that dominate global API production. These manufacturers typically supply the API to contract manufacturing organizations (CMOs) or directly to finished dosage form (FDF) manufacturers.

• Hefei Jirui Pharmaceutical Co., Ltd. (China): A significant producer of cytotoxic APIs, including Bendamustine Hydrochloride. The company is known for its large-scale manufacturing capabilities and adherence to international quality standards.
• Shandong Xinhua Pharmaceutical Co., Ltd. (China): A long-established pharmaceutical company with a broad API portfolio. Xinhua has demonstrated capabilities in producing complex APIs and navigating regulatory requirements.
• Wuhan Fortuna Chemical Co., Ltd. (China): Specializes in the production of APIs and intermediates. Fortuna is recognized for its focus on quality control and reliable supply chains.
• Qilu Pharmaceutical Co., Ltd. (China): A major integrated pharmaceutical company with substantial API manufacturing operations. Qilu is active in both domestic and international markets.
• Anuh Pharma Limited (India): An Indian API manufacturer with expertise in producing various therapeutic categories. Anuh Pharma focuses on regulatory compliance and efficient manufacturing processes.
• Divi's Laboratories Limited (India): While Divi's is a leading producer of generic APIs, their specific involvement with Bendamustine Hydrochloride needs direct confirmation through engagement. They possess extensive large-scale manufacturing and regulatory expertise.

These companies are chosen based on their public profiles, reported production capacities for oncology APIs, and participation in global pharmaceutical supply chains.

What are the regulatory and quality requirements for Bendamustine Hydrochloride API?

Manufacturing Bendamustine Hydrochloride API requires strict adherence to Good Manufacturing Practice (GMP) guidelines established by major regulatory bodies. These include:

• U.S. Food and Drug Administration (FDA): Requires compliance with 21 CFR Parts 210 and 211. Manufacturers must maintain Drug Master Files (DMFs) or Certificates of Suitability to the monographs of the European Pharmacopoeia (CEPs) for active substances.
• European Medicines Agency (EMA): Mandates compliance with EudraLex Volume 4. CEPs are commonly used for API registration in Europe.
• ICH Guidelines: International Council for Harmonisation guidelines, particularly Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), are foundational for quality management.

Key quality attributes for Bendamustine Hydrochloride API include:

• Purity: High levels of the active compound with stringent limits on specified and unspecified impurities.
• Impurity Profile: Identification and control of process-related impurities, degradation products, and residual solvents. The presence of genotoxic impurities requires particular scrutiny.
• Physical Properties: Consistent particle size distribution, polymorphic form, and moisture content are critical for downstream processing and bioavailability of the finished drug product.
• Stability: API must demonstrate stability under defined storage conditions, with established retest periods or expiry dates.

Recent regulatory actions, such as warning letters or import alerts issued by the FDA, can significantly impact an API supplier's ability to serve regulated markets. A thorough review of regulatory inspection history is essential.

What is the typical production capacity and scalability of Bendamustine Hydrochloride API?

The production capacity for Bendamustine Hydrochloride API is generally scalable, driven by market demand and the capabilities of specialized API manufacturers. Companies that produce cytotoxic APIs, like Bendamustine Hydrochloride, often have dedicated facilities or segregated production lines to prevent cross-contamination, which is a critical GMP requirement for potent compounds.

• Batch Sizes: Typical batch sizes can range from tens to hundreds of kilograms, depending on the manufacturer's reactor volumes and the specific synthesis route employed.
• Annual Capacity: While specific figures are proprietary, major manufacturers in China and India can produce metric tons of oncology APIs annually. This capacity is often shared across multiple products.
• Scalability Factors: Key considerations for scalability include:
  • Availability of raw materials and key intermediates.
  • Process robustness and validation across different scales.
  • Engineering controls for handling highly potent active pharmaceutical ingredients (HPAPIs).
  • Environmental, health, and safety (EHS) protocols.

Suppliers with established track records in producing similar cytotoxic compounds are better positioned to demonstrate scalability for Bendamustine Hydrochloride.

What are the critical raw materials and intermediates required for Bendamustine Hydrochloride synthesis?

The synthesis of Bendamustine Hydrochloride involves several key raw materials and intermediates. The reliable sourcing and quality control of these components are paramount to ensuring API production efficiency and consistency.

Primary building blocks often include:

• Nitrogen Mustard Moiety Precursors: Compounds that ultimately form the bis-(2-chloroethyl)amino group. Examples include derivatives of ethanolamine and chlorinating agents.
• Benzimidazole Moiety Precursors: Reagents used to construct the heterocyclic benzimidazole ring system. This can involve substituted anilines and formamide derivatives or equivalents.
• Specific Reagents:
  • 4-Aminobenzoic acid derivatives: Potentially used as a starting point for the benzimidazole core.
  • Phosphorus oxychloride (POCl3) or Thionyl chloride (SOCl2): Common chlorinating agents for forming the chloroethyl groups.
  • Acids and Bases: For hydrolysis, cyclization, and salt formation steps (e.g., hydrochloric acid, sodium hydroxide).
  • Solvents: Various organic solvents are used throughout the synthesis, including methanol, ethanol, acetone, and chlorinated solvents, requiring strict control over residual levels.

The complexity of the synthesis can lead to multiple intermediate stages, each requiring purification and characterization. The supply chain for these intermediates is a critical area of focus. Manufacturers often have backward integration for key intermediates or secure long-term supply agreements with specialized intermediate producers. Disruptions in the supply of any of these critical components can lead to significant delays and increased manufacturing costs.

What are the typical pricing structures and payment terms for bulk Bendamustine Hydrochloride API?

Pricing for bulk Bendamustine Hydrochloride API is influenced by several factors, including production volume, supplier tier (e.g., originator vs. generic API producer), current market demand, and the rigor of quality and regulatory documentation provided.

• Price per Kilogram: Prices can vary significantly. For established suppliers meeting stringent GMP and regulatory requirements, prices can range from several hundred to over a thousand U.S. dollars per kilogram. This is subject to negotiation based on volume and contract terms.
• Volume Discounts: Larger purchase orders typically command lower per-unit costs.
• Quality Documentation Costs: The cost associated with generating and maintaining DMFs, CEPs, and supporting regulatory filings is factored into the API price.
• Payment Terms: Standard payment terms often involve a combination of upfront payment and deferred payment.
  • Typical Structure: 30% to 50% upfront upon order placement, with the balance due within 30 to 60 days of shipment or upon receipt of goods.
  • Letters of Credit: May be required for large international orders or with new suppliers.
  • Negotiated Terms: Longer-term supply agreements can allow for more favorable payment terms.

It is imperative to obtain detailed quotations from multiple potential suppliers and to thoroughly vet their financial stability and supply chain reliability before committing to significant purchase orders.

What are the logistical and supply chain considerations for importing Bendamustine Hydrochloride API?

Importing bulk Bendamustine Hydrochloride API involves navigating complex international logistics, customs regulations, and specific handling requirements for pharmaceutical ingredients.

Key logistical considerations include:

• Shipping Methods:
  • Air Freight: Preferred for its speed, especially for urgent needs or smaller quantities. This is more expensive but ensures rapid transit.
  • Sea Freight: More cost-effective for larger volumes but significantly longer transit times.
• Packaging: API must be packaged in compliant, robust containers (e.g., double-lined drums) that protect against moisture, light, and contamination. Inert gas blanketing may be required for sensitive materials.
• Temperature Control: While Bendamustine Hydrochloride is generally stable at room temperature, specific storage and shipping temperature requirements (if any) must be adhered to, especially during transit. Temperature-controlled shipping solutions (reefers) may be necessary if excursions are a risk.
• Customs and Import Duties:
  • Import Licenses: Required by the importing country's health and customs authorities.
  • Tariffs and Duties: Vary by country and origin of goods. Pharmaceutical APIs may have specific duty rates.
  • Documentation: Comprehensive documentation is essential, including:
    • Commercial Invoice
    • Packing List
    • Certificate of Analysis (CoA) for each batch
    • Certificate of Origin
    • Bill of Lading or Air Waybill
    • DMF or CEP (if applicable)
    • Material Safety Data Sheet (MSDS)
• Regulatory Compliance: The importing entity must ensure that the API meets the regulatory standards of the destination country. This includes compliance with import regulations and potential pre-shipment inspections.
• Lead Times: Factor in production lead times (e.g., 4-12 weeks), shipping transit times (e.g., 2-5 days for air, 2-6 weeks for sea), and customs clearance time (e.g., 1-7 days). Total lead time can range from 6 to 16 weeks.
• Risk Mitigation:
  • Dual Sourcing: Establishing relationships with at least two qualified API suppliers mitigates risk from single-source dependencies.
  • Inventory Management: Maintaining a strategic buffer stock of API can protect against unforeseen supply disruptions.
  • Supplier Audits: Regular audits of overseas suppliers ensure continued adherence to quality and production standards.

Key Takeaways

Manufacturers in China and India are the primary suppliers of bulk Bendamustine Hydrochloride API. Key players include Hefei Jirui Pharmaceutical, Shandong Xinhua Pharmaceutical, and Wuhan Fortuna Chemical. Regulatory compliance, specifically adherence to GMP standards mandated by the FDA and EMA, is paramount. Production capacity is generally scalable, with manufacturers capable of producing metric tons of cytotoxic APIs annually. Critical raw materials include precursors for the nitrogen mustard and benzimidazole moieties, along with specific reagents and solvents. Pricing is influenced by volume, supplier tier, and quality documentation, with payment terms typically involving upfront and deferred components. Logistical considerations encompass air and sea freight, specialized packaging, customs compliance, and robust documentation. Dual sourcing and inventory management are essential for mitigating supply chain risks.

FAQs

1. What is the typical shelf life of Bendamustine Hydrochloride API? The shelf life, or retest period, for Bendamustine Hydrochloride API is typically determined by stability studies and can range from 2 to 5 years under controlled storage conditions. Manufacturers will specify the exact retest period on the Certificate of Analysis.

2. How is the purity of Bendamustine Hydrochloride API verified? Purity is verified through analytical testing, primarily High-Performance Liquid Chromatography (HPLC) to quantify the active ingredient and detect impurities. Other tests include Gas Chromatography (GC) for residual solvents, Karl Fischer titration for water content, and spectroscopic methods (e.g., IR, NMR) for identification.

3. Are there any specific handling precautions for Bendamustine Hydrochloride API due to its cytotoxic nature? Yes, due to its cytotoxic nature, Bendamustine Hydrochloride API requires stringent handling precautions. This includes manufacturing in dedicated or segregated facilities with advanced containment systems (e.g., isolators, fume hoods), appropriate personal protective equipment (PPE) for personnel, and specialized waste disposal procedures to prevent occupational exposure and environmental contamination.

4. Can a generic drug manufacturer directly use API from any GMP-certified supplier? While any GMP-certified supplier can be a potential source, generic drug manufacturers must conduct thorough due diligence. This includes reviewing the supplier's Drug Master File (DMF) or Certificate of Suitability (CEP), performing on-site audits, and verifying that the API's impurity profile and physical characteristics are consistent with those used in the innovator product or meet regulatory acceptance criteria for bioequivalence.

5. What are the implications of a Certificate of Suitability (CEP) for Bendamustine Hydrochloride API? A CEP, issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), certifies that an API complies with the requirements of the relevant European Pharmacopoeia monograph. For Bendamustine Hydrochloride API, a CEP simplifies the regulatory submission process for finished drug products in European countries that recognize CEPs, as it demonstrates that the API's quality has been evaluated and approved.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from [FDA Website - Specific URL for CGMP regulations would be inserted here if available] [2] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union. Retrieved from [EMA Website - Specific URL for EudraLex Volume 4 would be inserted here if available] [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7. [4] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from [FDA Website - Specific URL for DMF information would be inserted here if available] [5] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability (CEP). Retrieved from [EDQM Website - Specific URL for CEP information would be inserted here if available]